Prothena reported a net loss of $60.2 million for the first quarter of 2025, an improvement from the $72.2 million net loss in the first quarter of 2024. Total revenue significantly increased to $2.8 million, primarily due to collaboration revenue from Bristol Myers Squibb. The company ended the quarter with $418.8 million in cash, cash equivalents, and restricted cash.

Prothena reported a net loss of $58.0 million for the fourth quarter of 2024, an improvement from the $67.5 million net loss in the same period last year. Total revenue for the quarter was $2.1 million, up from $0.3 million in Q4 2023. The company ended the year with $472.2 million in cash, cash equivalents, and restricted cash.

Prothena reported a net loss of $59.0 million for the third quarter of 2024, compared to a net income of $21.9 million for the same period in 2023. Total revenue for the third quarter of 2024 was $1.0 million, primarily from collaboration revenue from Bristol Myers Squibb.

Prothena reported a net income of $66.9 million for the second quarter of 2024, a significant increase compared to the net loss of $54.6 million for the same period in 2023. Total revenue for the quarter was $132.0 million, primarily from collaboration revenue from Bristol Myers Squibb, compared to $4.0 million in the second quarter of 2023.

Prothena reported a net loss of $72.2 million for the first quarter of 2024, with total revenue of $0.1 million. The company's cash and restricted cash position at the end of the quarter was $548.7 million. The company continues to advance its pipeline of investigational therapeutics.

Prothena reported a net loss of $67.5 million in Q4 2023, compared to a net income of $6.3 million in Q4 2022. The loss was primarily due to increased research and development and general and administrative expenses. Total revenue was $0.3 million, including BMS collaboration revenue.

Prothena reported a net income of $21.9 million for the third quarter of 2023, a significant increase compared to a net loss of $45.8 million for the same period in 2022. The company's total revenue reached $84.9 million, primarily driven by collaboration revenue from Bristol Myers Squibb, including a $55 million payment for the exclusive worldwide license to PRX005. As of September 30, 2023, Prothena's cash and restricted cash position was $673.1 million.

Prothena reported a net loss of $54.6 million, with total revenue of $4.0 million primarily from collaboration revenue from Bristol Myers Squibb. The company's cash and restricted cash position at quarter-end was $661.3 million. They revised year-end cash guidance to approximately $600 million.

Prothena reported a net loss of $46.9 million for the first quarter of 2023, compared to a net loss of $36.3 million for the first quarter of 2022. Total revenue was $2.2 million, primarily from collaboration revenue from Bristol Myers Squibb. As of March 31, 2023, Prothena had $688.4 million in cash, cash equivalents and restricted cash.

Prothena reported a net income of $6.3 million for the fourth quarter of 2022, compared to a net loss of $33.2 million for the same period in 2021. The increase in revenue was primarily due to a $40.0 million milestone payment from Novo Nordisk and $9.9 million in BMS collaboration revenue.

Prothena reported a net loss of $45.8 million for the third quarter of 2022, with total revenue of $1.5 million. The company's cash and restricted cash position was $497.0 million as of September 30, 2022.

Prothena reported a net loss of $41.2 million for the second quarter of 2022, compared to a net income of $27.6 million for the same period in 2021. Total revenue for the quarter was $1.3 million, primarily from collaboration revenue from BMS, as compared to $60.1 million for the second quarter of 2021. The company's cash and restricted cash position was $510.1 million as of June 30, 2022.

Prothena reported a net loss of $36.3 million, compared to a net loss of $36.7 million for the first quarter of 2021. Total revenue was $1.2 million, primarily from collaboration revenue from Bristol Myers Squibb. The company's cash and restricted cash position was $544.3 million at the end of the quarter.

Prothena reported a net loss of $33.2 million for the fourth quarter of 2021, compared to a net loss of $30.7 million for the fourth quarter of 2020. Total revenue for the fourth quarter of 2021 was $1.2 million, compared to $0.4 million for the fourth quarter of 2020. The company's cash and restricted cash position was $580.4 million as of December 31, 2021.

Prothena reported a net income of $109.2 million compared to a net loss of $30.6 million for the third quarter of 2020. Total revenue was $139.2 million, including collaboration revenue of $78.5 million from Bristol Meyer Squibb and intellectual property revenue of $60.7 million from the sale of the intellectual property and related rights to the Company’s ATTR amyloidosis business and pipeline to Novo Nordisk.

Prothena reported a net income of $27.6 million for the second quarter of 2021, compared to a net loss of $26.3 million for the same period in 2020. The company's cash and restricted cash position at the end of the quarter was $402.5 million. Multiple strategic collaborations delivered milestones with a combined $200 million in partner payments this year from Roche, Bristol Myers Squibb and Novo Nordisk.

Prothena reported a net loss of $36.7 million, or $0.91 per share, for the first quarter of 2021. Total revenue was $0.2 million, and the company's cash and restricted cash position totaled $345.7 million as of March 31, 2021. The company expects full year 2021 net cash used in operating and investing activities to be $51 to $74 million and updates its projected year end cash balance to approximately $316 million.

Prothena reported a net loss of $30.7 million for the fourth quarter of 2020, compared to a net loss of $21.6 million for the same period in 2019. The company's cash and restricted cash position at the end of the quarter was $298.1 million.

Prothena reported a net loss of $30.6 million for the third quarter of 2020. Roche presented data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease and announced that prasinezumab will advance into a late-stage study.

Prothena reported a net loss of $26.3 million for the second quarter of 2020, compared to a net loss of $15.8 million for the same period in 2019. Total revenue was $0.2 million, primarily from the collaboration with Roche. As of June 30, 2020, Prothena had $336.6 million in cash, cash equivalents and restricted cash.

Prothena reported a net loss of $23.6 million for the first quarter of 2020, with total revenue of $0.1 million from its collaboration with Roche. The company's cash and restricted cash position was $355.4 million as of March 31, 2020.

Prothena reported a net loss of $21.6 million for the fourth quarter of 2019, compared to a net loss of $22.5 million for the same period in 2018. Total revenue, all from the collaboration with Roche, was $0.3 million for the fourth quarter of 2019, compared to $0.2 million for the fourth quarter of 2018. As of December 31, 2019, Prothena had $378.4 million in cash, cash equivalents and restricted cash.